Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma 204Lymphoma, Large B-Cell, Diffuse 168Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Hodgkin Disease 85Lymphoma, Non-Hodgkin 79Burkitt Lymphoma 67Lymphoma, Follicular 62Leukemia 51Lymphoma, Mantle-Cell 48Lymphoma, B-Cell 33Lymphoma, Large-Cell, Anaplastic 31Lymphoma, T-Cell, Peripheral 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 25Lymphoma, Large-Cell, Immunoblastic 23Recurrence 20Lymphoma, B-Cell, Marginal Zone 17Leukemia, Lymphocytic, Chronic, B-Cell 17Immunoblastic Lymphadenopathy 17Lymphoma, T-Cell 16Neoplasms 14Dendritic Cell Sarcoma, Interdigitating 14Leukemia, Biphenotypic, Acute 10HIV Infections 10Enteropathy-Associated T-Cell Lymphoma 9Waldenstrom Macroglobulinemia 8Lymphoma, T-Cell, Cutaneous 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma, Extranodal NK-T-Cell 7Cardiotoxicity 6

Interventions

Rituximab 9Cyclophosphamide 8fludarabine 5dacetuzumab 5blinatumomab 5Brentuximab Vedotin 4Bendamustine Hydrochloride 4ibrutinib 3fludarabine phosphate 3Vincristine 3Prednisone 3Melphalan 3Etoposide 3Doxorubicin 3tetulomab tetraxetan lu-177 2ponatinib 2cobomarsen 2acalabrutinib 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lutetium 2Ifosfamide 2Everolimus 2Carboplatin 2Busulfan 2Bone Marrow Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphatic Diseases × Doxorubicin × Lymphoid × Clear all
NCT04529772 2026-03-31

ESCALADE

Acerta Pharma BV

Phase 3 Active not recruiting
611 enrolled
Lymphoid

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Seagen Inc.

Phase 2 Terminated
24 enrolled 10 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 3 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡